Connor Clark & Lunn Investment Management Ltd. bought a new stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $137,000.
A number of other institutional investors have also added to or reduced their stakes in COLL. MERIAN GLOBAL INVESTORS UK Ltd acquired a new position in Collegium Pharmaceutical in the first quarter valued at approximately $26,000. First Quadrant L P CA lifted its stake in Collegium Pharmaceutical by 87.2% in the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after buying an additional 2,089 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Collegium Pharmaceutical by 67,855.6% in the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after buying an additional 6,107 shares during the period. Virginia Retirement Systems ET AL acquired a new position in Collegium Pharmaceutical in the first quarter valued at approximately $160,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in Collegium Pharmaceutical by 22.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after buying an additional 2,400 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.
Several equities analysts have issued reports on the company. ValuEngine raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.33.
In other news, EVP Scott Dreyer sold 2,857 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $12.31, for a total value of $35,169.67. Following the sale, the executive vice president now directly owns 40,596 shares in the company, valued at approximately $499,736.76. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David Hirsch sold 22,106 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the sale, the director now owns 64,223 shares in the company, valued at $748,197.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,963 shares of company stock worth $858,455. Insiders own 8.08% of the company’s stock.
Shares of COLL stock traded down $0.18 on Friday, hitting $11.92. 19,814 shares of the stock were exchanged, compared to its average volume of 219,851. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $404.99 million, a PE ratio of -10.08 and a beta of 0.52. Collegium Pharmaceutical Inc has a one year low of $10.01 and a one year high of $19.83. The firm’s 50 day moving average is $11.17 and its two-hundred day moving average is $13.26.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $75.04 million for the quarter, compared to analysts’ expectations of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, sell-side analysts expect that Collegium Pharmaceutical Inc will post -0.36 earnings per share for the current year.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: Understanding Options Trading
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.